Synthetic Immunomodulatory Peptides for Cancer Therapy - UB01-180-01


Synthetic non-native immunomodulatory mimics of known and unknown tumour antigens peptides with therapeutic and/or prophylactic effects on breast cancer

Technology Overview Breast cancer is the most frequently diagnosed cancer in women and the leading cause of cancer deaths in women worldwide. Current chemotherapeutic agents can have very severe side effects, thus a need to develop more specific cancer treatments. Researchers at Trinity College Dublin have identified synthetic immunomodulatory peptides (SIPs) indicated for cancer therapy through the use of a novel platform biopanning assay. SIPs are functional mimics of tumour-specific peptides that have been identified (a) de novo in a given patient or (b) through prior art and (c) in silico through contextual searches for a group of tumours. They function by stimulating the patients immune system to mount an effective anti-tumour response and may also be used prophylactically to prevent tumour incidence in certain familial forms of cancer.

Biopanning Assay: A variant biopanning assay was developed to affinity select recombinant M13-phages expressing a random oligopeptide library to identify 'recognisers' peptides of known and unknown molecules in tumour cells. The targets may be whole live human breast tumour cells, or their intact or degraded proteins. The target binding phages or their peptides are then screened to identify 'recogniser' peptides that differentially bind to human breast tumour as opposed to normal tissue. Selected 'recogniser' peptides are synthesised and used as a target to identify 'mimic' peptides [MPs] that bind to the 'recogniser' peptides. MPs are then characterised in functional assays to determine if they have the immune-stimulatory potential

Advantages:
  • Rapid identification of tumour antigen targets without the need for prior knowledge
  • Production of biological mimic peptides, to tumour antigens with proven immuno-stimulatory activity
  • Mimics are non-self thus avoiding self immune surveillance mechanisms
  • The mimic peptides are synthetic and thus do not contaminating biological molecules associated.
  • Mimics may be further modified to cater for various other immuno-modulatory parameters such as their stability.

    Development Stage: The SIPs have been characterised in functional assays to shown to stimulate T-cell responses in vitro using PBMCs.

    Principal Inventor(S):Drs. Ursula Bond, Tharappel James, Christina Siebke & Blanca Arnaiz

    Publications: Arnaiz B, Madrigal-Estebas L, Todryk S, James TC, Doherty DG, Bond U. A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens. J Immune Based Ther Vaccines. 2006 Apr 8;4:2.

    TCD REF: UB01-180-01

    Contact: Name: Emily Vereker, Ph.D Position: Technology Transfer Case Manager Tel: +353 1 896-4152 Email: emily.vereker@tcd.ie